Oculis to Present at the Stifel 2024 Healthcare Conference
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the Stifel 2024 Healthcare Conference. The event will take place on November 18-19, 2024, at the Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat on November 18 at 3:35 pm ET. The presentation will be available via live webcast, and the company will conduct one-on-one meetings with investors during the conference. Access to the fireside chat will be provided through Oculis' website under the Investors & Media section.
Oculis Holding AG (Nasdaq: OCS), una società biofarmaceutica globale focalizzata sulla cura degli occhi e sulla preservazione della vista, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. L'evento si svolgerà dal 18 al 19 novembre 2024, presso il Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, parteciperà a una chiacchierata informale il 18 novembre alle 15:35 ET. La presentazione sarà disponibile tramite webcast in diretta, e la società condurrà incontri individuali con gli investitori durante la conferenza. L'accesso alla chiacchierata sarà fornito tramite il sito web di Oculis nella sezione Investitori e Media.
Oculis Holding AG (Nasdaq: OCS), una empresa biofarmacéutica global enfocada en el cuidado ocular y la preservación de la vista, ha anunciado su participación en la Stifel 2024 Healthcare Conference. El evento se llevará a cabo del 18 al 19 de noviembre de 2024, en el Lotte New York Palace Hotel. Sylvia Cheung, Directora Financiera, participará en una charla informal el 18 de noviembre a las 3:35 pm ET. La presentación estará disponible a través de una transmisión en vivo, y la empresa llevará a cabo reuniones uno a uno con inversores durante la conferencia. El acceso a la charla se proporcionará a través del sitio web de Oculis en la sección de Inversores y Medios.
Oculis Holding AG (Nasdaq: OCS)는 눈 건강 및 시력 보존에 중점을 둔 글로벌 생물의약품 회사로, Stifel 2024 Healthcare Conference에 참여할 것이라고 발표했습니다. 이 행사는 2024년 11월 18일부터 19일까지 Lotte New York Palace Hotel에서 진행됩니다. Sylvia Cheung 최고 재무 책임자가 11월 18일 오후 3:35 ET에 일대일 대화에 참석할 예정입니다. 발표는 라이브 웹캐스트를 통해 제공되며, 회사는 회의 중에 투자자와의 일대일 미팅을 진행합니다. 일대일 대화에 대한 접근은 Oculis의 웹사이트 '투자자 및 미디어' 섹션을 통해 제공될 것입니다.
Oculis Holding AG (Nasdaq: OCS), une entreprise biopharmaceutique mondiale axée sur les soins oculaires et la préservation de la vue, a annoncé sa participation à la Stifel 2024 Healthcare Conference. L'événement se déroulera les 18 et 19 novembre 2024, au Lotte New York Palace Hotel. Sylvia Cheung, directrice financière, participera à une discussion informelle le 18 novembre à 15h35 ET. La présentation sera disponible par le biais d'une diffusion en direct, et l'entreprise organisera des réunions individuelles avec des investisseurs pendant la conférence. L'accès à la discussion sera fourni via le site Web d'Oculis dans la section Investisseurs et Médias.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf Augenpflege und den Erhalt des Sehens konzentriert, hat seine Teilnahme an der Stifel 2024 Healthcare Conference angekündigt. Die Veranstaltung findet am 18. und 19. November 2024 im Lotte New York Palace Hotel statt. Sylvia Cheung, Chief Financial Officer, wird am 18. November um 15:35 Uhr ET an einer informellen Gesprächsrunde teilnehmen. Die Präsentation wird über einen Live-Webcast verfügbar sein und das Unternehmen wird während der Konferenz Einzelgespräche mit Investoren führen. Der Zugang zur Gesprächsrunde wird über die Website von Oculis im Bereich Investoren und Medien bereitgestellt.
- None.
- None.
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.
Sylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live webcast of the fireside chat will be available here.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to request meetings. A link to access the fireside chat, when available, will be posted to Oculis website on the Events & Presentation page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com.
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577
FAQ
When is Oculis (OCS) presenting at the Stifel 2024 Healthcare Conference?
Where can I watch Oculis (OCS) Stifel Conference presentation?
Who will represent Oculis (OCS) at the Stifel 2024 Healthcare Conference?
How can investors meet with Oculis (OCS) management at the Stifel Conference?
